Compare ENLV & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENLV | ARMP |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.0M | 156.4M |
| IPO Year | 2014 | 1996 |
| Metric | ENLV | ARMP |
|---|---|---|
| Price | $4.20 | $4.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $20.00 | $15.00 |
| AVG Volume (30 Days) | ★ 280.7K | 263.2K |
| Earning Date | 05-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $2.35 |
| 52 Week High | $7.64 | $14.98 |
| Indicator | ENLV | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 39.57 |
| Support Level | $0.79 | $3.48 |
| Resistance Level | $7.64 | $7.67 |
| Average True Range (ATR) | 0.59 | 0.52 |
| MACD | -0.09 | 0.16 |
| Stochastic Oscillator | 50.64 | 55.33 |
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.